Psoriasis: A Systematic Review of Autoimmune Disorder


Authors : Narendra Pentu; A. Sharvani; V.Anil Kumar; B. Abhishek; T. Rama Rao

Volume/Issue : Volume 8 - 2023, Issue 10 - October

Google Scholar : https://tinyurl.com/m59kaznt

Scribd : https://tinyurl.com/4xwmezys

DOI : https://doi.org/10.5281/zenodo.10069162

Abstract : Psoriasis is a persistent, genetically influenced, relapsing, scaly, and inflammatory skin condition. It is an autoimmune, chronic inflammatory disease with a significant genetic component and an unknown etiology that is characterized by inflammation carried on by immune system failure. It is differentiated by continuous inflammation, which causes uncontrollable keratinocyte differentiation and proliferation. Around the world, 125 million people suffer from psoriasis, or between 1% and 3% of people worldwide. Psoriasis is thought to impact 60 million individuals worldwide, with 1.52% of the population in the UK being affected. Psoriasis is a chronic skin condition with a wide range of clinical manifestations, including plaque, flexural, guttate, pustular, and erythrodermic lesions. Plaque psoriasis is the most typical form of psoriasis; however, the illness is clinically heterogeneous in its symptoms and natural history depending on the patient's age, the environment in which they live, and the locations that are afflicted. Psoriatic arthritis, palmoplantar pustulosis, and generalized pustular psoriasis are three distinct but related phenotypes. For the treatment of mild to severe psoriasis, topical treatments such corticosteroids, vitamin D analogues, and tazarotene are effective. Treatment options for psoriasis include topical medications (corticosteroids and vitamin D analogues), phototherapy (psoralen and ultraviolet A radiation), basic systemic medications (methotrexate, cyclosporin, and acitretin), biological agents (TNF tumor necrosis factor, interleukin IL-17 and IL-23 inhibitors), and small molecules inhibitor therapies. Numerous comorbidities, such as depression, lymphoma, and cardiovascular disease, are linked to psoriasis. Although psoriasis cannot presently be cured, care should attempt to minimize physical and psychological suffering by treating patients early in the disease process, recognizing and avoiding related multimorbidity, instilling lifestyle improvements, and adopting a personalized approach to treatment.

Keywords : Autoimmune, keratinocyte, Erythrodermic Lesions, Plaque Psoriasis, Palmoplantar Pustulosis, Multimorbidity.

Psoriasis is a persistent, genetically influenced, relapsing, scaly, and inflammatory skin condition. It is an autoimmune, chronic inflammatory disease with a significant genetic component and an unknown etiology that is characterized by inflammation carried on by immune system failure. It is differentiated by continuous inflammation, which causes uncontrollable keratinocyte differentiation and proliferation. Around the world, 125 million people suffer from psoriasis, or between 1% and 3% of people worldwide. Psoriasis is thought to impact 60 million individuals worldwide, with 1.52% of the population in the UK being affected. Psoriasis is a chronic skin condition with a wide range of clinical manifestations, including plaque, flexural, guttate, pustular, and erythrodermic lesions. Plaque psoriasis is the most typical form of psoriasis; however, the illness is clinically heterogeneous in its symptoms and natural history depending on the patient's age, the environment in which they live, and the locations that are afflicted. Psoriatic arthritis, palmoplantar pustulosis, and generalized pustular psoriasis are three distinct but related phenotypes. For the treatment of mild to severe psoriasis, topical treatments such corticosteroids, vitamin D analogues, and tazarotene are effective. Treatment options for psoriasis include topical medications (corticosteroids and vitamin D analogues), phototherapy (psoralen and ultraviolet A radiation), basic systemic medications (methotrexate, cyclosporin, and acitretin), biological agents (TNF tumor necrosis factor, interleukin IL-17 and IL-23 inhibitors), and small molecules inhibitor therapies. Numerous comorbidities, such as depression, lymphoma, and cardiovascular disease, are linked to psoriasis. Although psoriasis cannot presently be cured, care should attempt to minimize physical and psychological suffering by treating patients early in the disease process, recognizing and avoiding related multimorbidity, instilling lifestyle improvements, and adopting a personalized approach to treatment.

Keywords : Autoimmune, keratinocyte, Erythrodermic Lesions, Plaque Psoriasis, Palmoplantar Pustulosis, Multimorbidity.

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe